ClinicalTrials.gg
RecruitingNCT07481357Updated May 20, 2026

A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma

A Phase 1 interventional study of DA-3501 in Gastric (Stomach) Cancer, GastroEsophageal Cancer and Pancreatic Ductal Adenocarcinoma (mPDAC), sponsored by Dong-A ST Co., Ltd.. Recruiting at 3 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 521 studies in Stomach Neoplasms with a site in Korea, Republic of — 78 open to participants now, 116 under way, 20 of them phase 3. Stomach Neoplasms · Korea, Republic of.

Planned enrollment
328th of 448
51 · median 95
Started
2026
with 12 others
Phase 1
49 of 521
9 open now
Primary completion
2028-02
later than 82 of 115 live
Registered
510th of 521
by date

Among the 521 studies in Stomach Neoplasms with a site in Korea, Republic of, this one is the 328th largest by planned enrollment of the 448 interventional ones that give a count, is one of 13 that started in 2026, is one of 49 in phase 1, reaches primary completion later than 82 of the 115 other live ones, and was the 510th registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

78 of the 521 studies in Stomach Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

72 more — sign in →

All 78 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 521 studies in Stomach Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the MTD or OBED of DA-3501 given in Q3W to determine a wRP2D in patients with advanced CLDN18.2 expressing (CLDN18.2+) GC/GEJ and advanced CLDN18.2+ PDAC.

Participants will receive the assigned dose once every three weeks and, according to the study procedures, will undergo tumor assessments as well as safety assessments, PK evaluations, and ADA testing.

03

Conditions studied

  • Gastric (Stomach) Cancer
  • GastroEsophageal Cancer
  • Pancreatic Ductal Adenocarcinoma (mPDAC)

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 19 years
  2. or cytologically documented advanced CLDN18.2+ GC/GEJ adenocarcinoma or advanced CLDN18.2+ PDAC
  3. as defined by version 1.1 (RECIST v1.1)
  4. ≥12 weeks as judged by the Investigator

Exclusion criteria

Exclusion Criteria:

  1. Cardiac abnormalities
  2. Gastrointestinal abnormalities
  3. Active and bacterial, fungal, or viral infection, including known virus (HBV), known virus (HCV), known (HIV).
  4. Active systemic infection requiring IV antibiotics therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Participants will receive DA-3501 at dose level 1 administered intravenously once every three weeks.

    Drug: DA-3501

  • Experimental
    Dose Level 2

    Drug: DA-3501

  • Experimental
    Dose Level 3

    Drug: DA-3501

  • Experimental
    Dose Level 4

    Drug: DA-3501

  • Experimental
    Dose Level 5

    Drug: DA-3501

  • Experimental
    Dose Level 6

    Drug: DA-3501

  • Experimental
    Dose Level 7

    Drug: DA-3501

  • Experimental
    Dose Level 8

    Drug: DA-3501

  • Experimental
    Dose Level 9

    Drug: DA-3501

  • Experimental
    Dose Level 10

    Drug: DA-3501

  • Experimental
    Dose Level 11

    Drug: DA-3501

Interventions

  • DrugDA-3501

    Participant will receive DA-3501 at the assigned dose level administered intravenously once every three weeks.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) based on Dose-Limiting Toxicities (DLTs) during Cycle 1

    Time frame: 21 days

  2. Optimal Biological Effective Dose (OBED) Based on best Overall Response Rate (ORR)

    Time frame: 42 days

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.

Of 167 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 21 months is below that.

Counting every sponsor, half of 242 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 18, 2026
StartActual
May 18, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2029
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07481357
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
May 18, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
May 20, 2026

Study contacts

Jiwon Shin
Contact
jiwon_shin@donga.co.kr
82-2-920-8768

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion